Non-small cell lung cancer

News

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the d

News

Roche seeks early-stage lung cancer use for Alecensa

Roche plans to file its Alecensa drug for use in early-stage ALK-positive non-small cell lung cancer (NSCLC), potentially making it the first targeted therapy for these pa

News

'Inadvertent' leak teases survival benefit for Roche's TIGIT

In an unusual development, Roche has put out a statement this morning acknowledging an "inadvertent disclosure" of data from its SKYSCRAPER-01 study of anti-TIGIT drug tir

News

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

AstraZeneca and partner Daiichi Sankyo have their first phase 3 data for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) – in lung cancer –

Oncology

ASCO 2023 – Gregory Lubiniecki

With its blockbuster checkpoint inhibitor Keytruda, Merck has been a star of the show at many ASCO conferences in recent years.

News

ASCO: AZ gets a practice-changing win in lung cancer

The question of whether adjuvant treatment with AstraZeneca’s Tagrisso can help patients with EGFR-positive non-small cell lung cancer live longer has finally been answere

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

Roche seeks early-stage lung cancer use for Alecensa

'Inadvertent' leak teases survival benefit for Roche's TIGIT

AZ, Daiichi’s TROP2 drug hits the mark in lung cancer

ASCO 2023 – Gregory Lubiniecki

ASCO: AZ gets a practice-changing win in lung cancer

UK backs start-up Potential Sciences' AI-powered drug hunt

Discover a new era of healthcare panel engagement: Grounded ...

Non-small cell lung cancer

Editor's Picks